NSCLC Clinical Trials in Shanghai, Shanghai Municipality
10 recruitingShanghai, Shanghai Municipality, China
Showing 1–10 of 10 trials
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 2
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
NSCLC
Shanghai Chest Hospital124 enrolled1 locationNCT05798845
Recruiting
Phase 2
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
NSCLCImmunotherapyStereotactic Body Radiation Therapy (SBRT)
Fudan University27 enrolled1 locationNCT06738160
Recruiting
Phase 2
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NSCLC
HC Biopharma Inc.50 enrolled1 locationNCT07169552
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
NSCLCNSCLC Stage IVNSCLC, Recurrent
Shanghai Chest Hospital500 enrolled2 locationsNCT05701787
Recruiting
Phase 1Phase 2
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
NSCLC
Suzhou Junjing BioSciences Co., Ltd.42 enrolled1 locationNCT06940401
Recruiting
Phase 2
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NSCLCPD-1
Shanghai Pulmonary Hospital, Shanghai, China50 enrolled1 locationNCT06479759
Recruiting
Phase 2
Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC
NSCLC
Shanghai Pulmonary Hospital, Shanghai, China54 enrolled2 locationsNCT06424821
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728